Abstract
The study aim was to explore the role of DEK in tumor progression and prognostic of hepatocellular carcinoma (HCC). DEK protein in 178 samples of HCC was evaluated by immunohistochemical method. Additionally, the correlation between DEK expression and the clinicopathological features was evaluated by x(2) test or Fisher's exact test, the survival rates were calculated by the Kaplan-Meier method, and the relationship between prognostic factors and patient survival was also by the Cox analysis. DEK protein expression was noted in 86 cases of HCC, and 61 cases of normal liver tissues. DEK positive rate were closely correlated with the tumor size, grade, AJCC stage and survival rate (P<0.05, respectively). HCC with large tumor, lower grade, and late-stage, concomitant with DEK expression, had the lowest 5-years survival rate than HCC with above factors but without DEK expression (P<0.01, respectively). DEK expression emerged as significant independent hazard factors for survival in HCC (P<0.01). DEK could promote aggressiveness of cancer behavior, and hence poor prognosis of the HCC. It might be an independent poor prognostic factor and can serve as a useful new therapeutic biomarker.
Highlights
Hepatocellular carcinoma (HCC) is the most common primary hepatic malignancy, especially in Africa and Asia.[1,2] Despite many years of sustained efforts, the long-term outcome employing current1
No statistical difference was found between DEK expression and age, gender, cirrhosis status, lymph node metastasis (LN), and portal vein tumor thrombus (PVTT) (P>0.05, respectively)
We found that HCC with large tumor, lower grade, and tumor stage concomitant with DEK expression showed significantly lower 5-years survival rate than HCC with above factors but without DEK expression (Fig. 2B-D, P=0.007, P=0.001, and P0.05)
Summary
Hepatocellular carcinoma (HCC) is the most common primary hepatic malignancy, especially in Africa and Asia.[1,2] Despite many years of sustained efforts, the long-term outcome employing current1.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
